Wegovy Heart Benefits Unaffected by Frailty in Trial

Semaglutide, marketed as Wegovy, demonstrated significant cardiovascular benefits for adults with existing heart disease and overweight or obesity, regardless of their frailty level. This finding emerged from a secondary analysis of data from the landmark SELECT trial, which concluded at week 104. The original SELECT trial enrolled 17,604 participants aged 45 years and older who had established cardiovascular disease and a body mass index (BMI) of 27 or higher, excluding those with diabetes. Participants were randomized to receive either 2.4 mg of subcutaneous semaglutide once weekly or a placebo, in addition to standard care.

The secondary analysis specifically examined the impact of frailty, a condition characterized by decreased physiological reserve and increased vulnerability to stressors, on the efficacy of semaglutide. Frailty was assessed using a validated index, and participants were categorized based on their frailty status. The results indicated that the primary composite endpoint of the SELECT trial—comprising cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke—was significantly reduced by semaglutide treatment. This reduction in major adverse cardiovascular events (MACE) was observed consistently across participants, whether they were classified as frail, pre-frail, or robust. This suggests that the weight loss and metabolic improvements induced by semaglutide confer protection against cardiovascular events even in more vulnerable patient populations.

While the SELECT trial's primary objective was to evaluate the cardiovascular outcomes of semaglutide in this specific patient group, this subsequent analysis provides crucial insights into its applicability to a broader spectrum of individuals with cardiovascular disease and excess weight. The drug, developed by Novo Nordisk, is a glucagon-like peptide-1 (GLP-1) receptor agonist that promotes weight loss through mechanisms including appetite suppression and increased satiety. The trial data showed a statistically significant reduction in MACE for the semaglutide group compared to placebo, with the benefit persisting throughout the 104-week study period. The consistency of these benefits across different frailty levels underscores the potential of semaglutide as a therapeutic option for a wide range of patients at high cardiovascular risk.

Further investigation into the specific mechanisms by which semaglutide mitigates cardiovascular risk in frail individuals may be warranted. However, the current findings from the SELECT trial's secondary analysis offer strong evidence that clinicians can prescribe Wegovy to overweight or obese patients with cardiovascular disease without concern that frailty will negate its cardioprotective effects. This broadens the potential patient population that could benefit from this medication, aligning with public health goals to reduce the burden of cardiovascular disease and obesity-related comorbidities.